A detailed history of Royal Bank Of Canada transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 12,343 shares of TCRX stock, worth $29,746. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,343
Previous 3,611 241.82%
Holding current value
$29,746
Previous $21,000 190.48%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.97 - $7.49 $43,398 - $65,402
8,732 Added 241.82%
12,343 $61,000
Q2 2024

Aug 14, 2024

BUY
$5.85 - $9.51 $21,124 - $34,340
3,611 New
3,611 $21,000
Q3 2022

Nov 14, 2022

BUY
$2.62 - $4.39 $482 - $807
184 New
184 $1,000
Q2 2022

Aug 15, 2022

SELL
$1.65 - $3.58 $1,650 - $3,580
-1,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$6.17 - $13.48 $6,170 - $13,480
1,000 New
1,000 $8,000

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $45.6M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.